Streetbeat News

Equity Actions

ANTX

AN2 Therapeutics, Inc. (NASDAQ:ANTX) has announced the pricing of an underwritten offering of 7,777,778 shares of its common stock at $9.00 per share, a premium from today's closing price. The gross proceeds from the offering are expected to be approximately $70.0 million. The offering is expected to close on August 18, 2023. Investors include RA Capital Management, TCGX, Frazier Life Sciences, Marshall Wace, Adage Capital Partners LP, Avidity Partners, Janus Henderson Investors and Surveyor Capital (a Citadel company).

Portfolio Pulse from Happy Mohamed

August 16, 2023 | 4:17 am

ETHUSD

Former President Donald Trump is reported to own up to $5 million worth of Ethereum (ETH), according to financial disclosures for 2023 posted by Citizens for Responsibility and Ethics in Washington (CREW). The disclosures also revealed that Trump earned $2.8 million from his ETH holdings and more than $4.8 million from licensing fees associated with nonfungible token (NFT) collections featuring his image. This resulted in a net profit of around $7.6 million for Trump from crypto-related ventures.

Portfolio Pulse from Mehab Qureshi

August 16, 2023 | 3:57 am

TSLA

Tesla Inc. is preparing to launch its Full Self-Driving (FSD) Beta in China, despite potential regulatory challenges. The company is hiring a new team to manage the rollout, including an operations team and data labelers. The FSD package, priced at $15,000, has been on sale for nearly a decade but has not yet fully delivered autonomous driving. The launch in China, Tesla's largest market outside North America, is not expected until next year due to regulatory hurdles.

Portfolio Pulse from Benzinga Neuro

August 16, 2023 | 2:53 am

ACHR

ADPT

BEAM

DNA

NTLA

TSLA

Ark Invest, led by Cathie Wood, has sold nearly $440,000 worth of Tesla Inc (TSLA) shares, despite recent bullish projections for the company. The firm also purchased $4.1 million worth of shares of Archer Aviation Inc (ACHR). Other trades include purchases of shares in Ginkgo Bioworks Holdings Inc (DNA), Intellia Therapeutics Inc (NTLA), Beam Therapeutics Inc (BEAM), and Adaptive Biotechnologies (ADPT).

Portfolio Pulse from Benzinga Neuro

August 16, 2023 | 2:22 am

DTIL

Precision BioSciences (NASDAQ:DTIL) has completed a strategic transaction with Imugene Limited for global rights to Azercabtagene Zapreleucel (azer-cel), Precision's lead allogeneic CAR T candidate, for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population. Precision is eligible to receive up to $227 million in upfront economics and milestone payments for azer-cel, in addition to double-digit royalties on sales.

Portfolio Pulse from Charles Gross

August 15, 2023 | 11:50 pm

FLHLF

JAQC

Filament Health (OTCQB:FLHLF) has released its Q1 2023 financial results, showing a decrease in total cash and an accumulated deficit of $19.6 million. The company has expressed uncertainties about its ability to execute its business plan and continue operations without additional financing. Filament has announced its intention to list on the NASDAQ through a business combination with Jupiter Acquisition Corp. (NASDAQ:JAQC). The company has also reported progress in its drug development program, including FDA approval of two clinical studies and a global licensing agreement with NeoLumina Bioscience Inc.

Portfolio Pulse from Lara Goldstein

August 15, 2023 | 10:21 pm

TLLTF

TILT Holdings Inc (OTCQX:TLLTF) has decided to cut ties with its social equity brands, including Her Highness, Highsman, and Black Buddha Cannabis. The decision, under the new leadership of interim CEO Tim Conder, has sparked controversy, with stakeholders questioning Tilt's commitment to diversity and social equity. The company also plans to sever ties with the New York Shinnecock Nation and shift its focus to its Jupiter vape business. TLLTF shares were trading 11.35% down at $0.025 per share at the time of publishing.

Portfolio Pulse from Joana Scopel

August 15, 2023 | 9:36 pm

ARHS

Freeman Spogli & Co. affiliated selling stockholders have started an underwritten public offering of 12 million shares of Arhaus. They also plan to give underwriters a 30-day option to buy up to an additional 1.8 million shares.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 8:51 pm

OCGN

Ocugen has announced that Quan Vu is no longer serving as CFO/Chief Business Officer, and as Principal Financial Officer and Principal Accounting Officer, effective August 14, 2023. The company's Board of Directors has appointed Shankar Musunuri, the Company’s Chairman, Chief Executive Officer & Co-Founder, as the interim principal financial officer.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 8:28 pm

LGL

The LGL Group, Inc. (NYSE:LGL) has appointed Timothy Foufas as the Co-CEO. The company also announced the election of Ms. Darlene DeRemer and Mr. Herve Francois to the Board of Directors, effective immediately.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 8:26 pm